LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Ten cases had leptin deficiency (12.5%), while 18 cases showed elevated leptin levels (22.5%).
|
31483094 |
2020 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
However, short-term leptin substitution can increase the blood pressure and heart rate in obese humans with leptin deficiency, indicating that leptin plays at least an additive role in obesity-associated hypertension.
|
31357197 |
2019 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Preterm delivery leads to premature separation from the maternal and placental leptin source predisposing infants to postnatal leptin deficiency, but this has not been fully described.
|
30845123 |
2019 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
While leptin replacement therapy fails to provide substantial benefit in common obesity, it is an effective treatment for congenital leptin deficiency and states of acquired leptin deficiency such as lipodystrophy.
|
30475221 |
2019 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We propose that this expanded framework for understanding the mechanisms underlying leptin deficiency arising from genetic mutations may be useful in designing therapeutics for leptin-associated disorders.
|
29950524 |
2018 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
The observation of leptin deficiency in patients with lipodystrophy and the potential of leptin replacement to rescue metabolic abnormalities in animal models of lipodystrophy were followed by the first clinical study of leptin therapy in patients with severe lipodystrophy.
|
30370487 |
2018 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Because uncontrolled diabetes is associated with both leptin deficiency and hyperglucagonemia, and because intracerebroventricular (ICV) leptin administration reverses both hyperglycemia and hyperglucagonemia in this setting, we hypothesized that deficient leptin inhibition of LPBNCCK neurons drives activation of this LPBN→VMN circuit and thereby results in hyperglucagonemia.
|
29438473 |
2018 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Future studies should assess leptin as a subfertility treatment in human leptin-deficiency disorders.
|
30021121 |
2018 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Changes in Satiety Hormones in Response to Leptin Treatment in a Patient with Leptin Deficiency.
|
29996141 |
2018 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Measurement of immunofunctional leptin to detect and monitor patients with functional leptin deficiency.
|
28007844 |
2017 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
This dual-cassette vector achieves highly selective transduction of visceral fat while severely restricting off-target transduction of liver.As proof of efficacy, i.p. administration of an adipose-targeting Rec2 vector harboring the leptin gene corrects leptin deficiency, obesity, and metabolic syndromes of <i>ob</i>/<i>ob</i> mice.
|
28702474 |
2017 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Leptin deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes.
|
27488462 |
2017 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Experimental studies using animal models of a low leptin state such as leptin deficiency have shown that leptin regulates sleep architecture, upper airway patency, ventilatory function, and hypercapnic ventilatory response.
|
28796527 |
2017 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The leptin staining intensity suggested that ART alone may lead to increased leptin expression, whereas ART combined with a HCD may cause leptin deficiency.
|
28606728 |
2017 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Repleting leptin reverses the starvation signal both in physiologic starvation and in obesity resulting from genetic leptin deficiency.
|
28648981 |
2017 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Although the effects of leptin deficiency on reproduction are well recognized, the effect of excess leptin on male reproductive function is not clear.
|
27324433 |
2017 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Recombinant methionyl human leptin (metreleptin) therapy was shown to improve hyperglycaemia, dyslipidaemia and insulin sensitivity in patients with lipodystrophic syndromes, but its effects on insulin secretion remain controversial.We used dynamic intravenous (i.v.) clamp procedures to measure insulin secretion, adjusted to insulin sensitivity, at baseline and after 1 year of metreleptin therapy, in 16 consecutive patients with lipodystrophy, diabetes and leptin deficiency.
|
26584826 |
2016 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Leptin deficiency protected ob/ob mice from the development of autoantibodies and renal disease and increased the frequency of immunoregulatory T cells (Tregs) compared with leptin-sufficient WT mice.
|
27588900 |
2016 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
GeneticVariation
|
disease |
UNIPROT |
Biologically inactive leptin and early-onset extreme obesity.
|
25551525 |
2015 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Leptin is not able to treat typical obesity; however, it is effective for reversing leptin deficiency-induced obesity and is possibly useful in lipodystrophy.
|
26313897 |
2015 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
GermlineCausalMutation
|
disease |
ORPHANET |
Monogenic forms of childhood obesity due to mutations in the leptin gene.
|
26567097 |
2014 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Importantly, administration of recombinant human leptin in leptin deficiency represents the first mechanistically based targeted therapy for obesity and has provided immense clinical benefits for the patients concerned.
|
25232148 |
2014 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Study 1: 15 lean subjects received placebo or physiologic replacement-dose recombinant human leptin (metreleptin) following short term complete caloric deprivation to induce severe hypoleptinemia; Study 2: 7 women with relative leptin deficiency due to strenuous exercise or low weight received 3 months of metreleptin; Study 3: 17 women with relative leptin deficiency were randomized to receive metreleptin or placebo over 9 months.
|
24703486 |
2014 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
Leptin's physiological functions as well as deleterious effects in states of leptin deficiency or hyperleptinemia are emphasized.
|
23374894 |
2013 |
LEPTIN DEFICIENCY OR DYSFUNCTION
|
0.800 |
Biomarker
|
disease |
BEFREE |
In uncontrolled human studies, low leptin levels are associated with impaired immune responses and reduced T-cell counts; however, the effects of leptin replacement on the adaptive immune system have not yet been reported in the context of randomized, controlled studies and/or in conditions of chronic acquired leptin deficiency.
|
23382191 |
2013 |